1.
J Pediatr Hematol Oncol
; 39(2): 156-158, 2017 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28060107
Assuntos
Anti-Infecciosos/uso terapêutico , Procedimentos Cirúrgicos de Citorredução , Leucostasia/tratamento farmacológico , Pneumopatias/tratamento farmacológico , Criança , Citarabina/uso terapêutico , Humanos , Leucostasia/patologia , Leucostasia/cirurgia , Pneumopatias/patologia , Pneumopatias/cirurgia , Masculino , Prognóstico
2.
J Pediatr Hematol Oncol
; 39(2): e59-e61, 2017 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27606438
RESUMO
Vitamin D receptor (VDR) polymorphisms are found more commonly in some tumor types than in healthy individuals, suggesting that some polymorphisms (Cdx2, Fok1, Bsm1, Apa1, Taq1) contribute to tumor development. There is no previous report on VDR polymorphism in Hodgkin's lymphoma (HL) patients. VDR polymorphism patterns in 95 pediatric HL cases with 100 healthy controls were compared. No statistically significant difference was found between the patient group and control group in terms of Cdx2, Fok1, Bsm1, Apa1, and Taq1 polymorphisms (P>0.5). Our findings suggest that VDR polymorphisms may not play a role in HL development.